Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Original Article

R.S. Finn, S. Qin, M. Ikeda, P.R. Galle, M. Ducreux, T.-Y. Kim, M. Kudo, V. Breder, P. Merle, A.O. Kaseb, D. Li, W. Verret, D.-Z. Xu, S. Hernandez, J. Liu, C. Huang, S. Mulla, Y. Wang, H.Y. Lim, A.X. Zhu, and A.-L. Cheng

N Engl J Med 2020;382:1894-1905

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
05/13/2020
Course expires: 
05/14/2022

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation

Course closed

This course closed on Saturday, May 14, 2022 - 11:59pm.